X0508 4 2026-01-12 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001831216 Myles David C. C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST SAN FRANCISCO CA 94103 false true false false CH. DISCOV. & NON-CLIN DEV OFF 0 Common Stock 2026-01-12 4 S 0 10000 28.34 D 144846 I See Footnote Common Stock 2026-01-13 4 M 0 50000 4.87 A 592761 D Common Stock 2026-01-13 4 S 0 49800 27.60 D 542961 D Common Stock 2026-01-13 4 S 0 200 28.49 D 542761 D Common Stock 2026-01-14 4 M 0 50000 4.87 A 592761 D Common Stock 2026-01-14 4 S 0 14997 28.60 D 577764 D Common Stock 2026-01-14 4 S 0 35003 28.99 D 542761 D Common Stock 12831 I See Footnote Stock Option (Right to Buy) 4.87 2026-01-13 4 M 0 50000 0 D 2033-01-31 Common Stock 50000 100000 D Stock Option (Right to Buy) 4.87 2026-01-14 4 M 0 50000 0 D 2033-01-31 Common Stock 50000 50000 D The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held by Myles Properties Inc., of which the Reporting Person is President. On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4. The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Shane Kovacs, Attorney-in-Fact 2026-01-14